Free Trial

BioXcel Therapeutics (BTAI) Competitors

$1.18
-0.01 (-0.84%)
(As of 04:29 PM ET)

BTAI vs. KPTI, GBIO, BMEA, TELO, RGLS, XBIT, ALIM, OGI, RIGL, and RZLT

Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Karyopharm Therapeutics (KPTI), Generation Bio (GBIO), Biomea Fusion (BMEA), Telomir Pharmaceuticals (TELO), Regulus Therapeutics (RGLS), XBiotech (XBIT), Alimera Sciences (ALIM), Organigram (OGI), Rigel Pharmaceuticals (RIGL), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.

BioXcel Therapeutics vs.

Karyopharm Therapeutics (NASDAQ:KPTI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

Karyopharm Therapeutics received 289 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.09% of users gave Karyopharm Therapeutics an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.

CompanyUnderperformOutperform
Karyopharm TherapeuticsOutperform Votes
527
72.09%
Underperform Votes
204
27.91%
BioXcel TherapeuticsOutperform Votes
238
67.23%
Underperform Votes
116
32.77%

Karyopharm Therapeutics currently has a consensus price target of $4.80, suggesting a potential upside of 338.36%. BioXcel Therapeutics has a consensus price target of $16.71, suggesting a potential upside of 1,275.66%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Karyopharm Therapeutics
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
BioXcel Therapeutics
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Karyopharm Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 4.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$146.03M0.93-$143.10M-$1.27-0.86
BioXcel Therapeutics$1.38M32.09-$179.05M-$5.18-0.23

Karyopharm Therapeutics has a net margin of -104.18% compared to Karyopharm Therapeutics' net margin of -8,715.72%. BioXcel Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics-104.18% N/A -57.80%
BioXcel Therapeutics -8,715.72%-890.63%-154.37%

In the previous week, BioXcel Therapeutics had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 1 mentions for Karyopharm Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.34 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Karyopharm Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioXcel Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Karyopharm Therapeutics beats BioXcel Therapeutics on 11 of the 17 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTAI vs. The Competition

MetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$44.29M$7.09B$5.12B$8.45B
Dividend YieldN/A2.74%5.26%4.10%
P/E Ratio-0.2313.37134.7315.44
Price / Sales32.09228.102,330.8869.68
Price / CashN/A20.4831.6629.44
Price / Book-0.625.544.714.23
Net Income-$179.05M$146.61M$108.86M$215.42M
7 Day Performance-3.28%0.36%-0.55%-0.34%
1 Month Performance-36.56%-2.49%-3.88%-2.81%
1 Year Performance-93.74%-8.92%-3.97%-0.23%

BioXcel Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KPTI
Karyopharm Therapeutics
3.1991 of 5 stars
$0.93
-4.1%
$4.80
+416.1%
-44.7%$115.90M$146.03M-0.73325
GBIO
Generation Bio
2.0677 of 5 stars
$2.70
-7.5%
$8.00
+196.3%
-50.8%$179.63M$5.90M-1.06174
BMEA
Biomea Fusion
3.514 of 5 stars
$4.85
-4.7%
$28.25
+482.5%
-81.9%$174.33MN/A-1.36110Analyst Forecast
News Coverage
TELO
Telomir Pharmaceuticals
0 of 5 stars
$5.58
+3.9%
N/AN/A$165.22MN/A0.001Gap Down
RGLS
Regulus Therapeutics
1.5566 of 5 stars
$2.48
+4.6%
$7.25
+192.3%
+53.0%$162.36MN/A-1.7030Analyst Forecast
News Coverage
High Trading Volume
XBIT
XBiotech
0 of 5 stars
$5.26
-13.5%
N/A-24.8%$160.22M$4.01M-5.1682High Trading Volume
ALIM
Alimera Sciences
2.4942 of 5 stars
$3.05
-6.2%
$8.00
+162.3%
+102.9%$159.79M$80.75M-1.94154Analyst Forecast
News Coverage
OGI
Organigram
0 of 5 stars
$1.54
+2.0%
N/A-1.6%$159.76M$120.01M-1.64984News Coverage
RIGL
Rigel Pharmaceuticals
2.6013 of 5 stars
$0.90
-2.2%
$5.81
+543.9%
-43.1%$158.34M$116.88M-7.52147Analyst Forecast
Options Volume
News Coverage
Gap Down
RZLT
Rezolute
3.1943 of 5 stars
$3.88
+0.8%
$9.67
+149.1%
+91.9%$155.70MN/A-3.4057Positive News

Related Companies and Tools

This page (NASDAQ:BTAI) was last updated on 6/25/2024 by MarketBeat.com Staff

From Our Partners